Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 7
2010 7
2011 6
2012 4
2013 3
2014 2
2015 6
2016 10
2017 17
2018 25
2019 28
2020 41
2021 65
2022 37
2023 26
2024 27
2025 51
2026 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

321 results

Results by year

Filters applied: . Clear all
Page 1
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.
Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, Moreau P, Dingli D, Cole C, Lonial S, Dimopoulos M, Stewart AK, Richter J, Vij R, Tuchman S, Raab MS, Weisel KC, Delforge M, Cornell RF, Kaminetzky D, Hoffman JE, Costa LJ, Parker TL, Levy M, Schreder M, Meuleman N, Frenzel L, Mohty M, Choquet S, Schiller G, Comenzo RL, Engelhardt M, Illmer T, Vlummens P, Doyen C, Facon T, Karlin L, Perrot A, Podar K, Kauffman MG, Shacham S, Li L, Tang S, Picklesimer C, Saint-Martin JR, Crochiere M, Chang H, Parekh S, Landesman Y, Shah J, Richardson PG, Jagannath S. Chari A, et al. Among authors: gavriatopoulou m. N Engl J Med. 2019 Aug 22;381(8):727-738. doi: 10.1056/NEJMoa1903455. N Engl J Med. 2019. PMID: 31433920 Clinical Trial.
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.
Grosicki S, Simonova M, Spicka I, Pour L, Kriachok I, Gavriatopoulou M, Pylypenko H, Auner HW, Leleu X, Doronin V, Usenko G, Bahlis NJ, Hajek R, Benjamin R, Dolai TK, Sinha DK, Venner CP, Garg M, Gironella M, Jurczyszyn A, Robak P, Galli M, Wallington-Beddoe C, Radinoff A, Salogub G, Stevens DA, Basu S, Liberati AM, Quach H, Goranova-Marinova VS, Bila J, Katodritou E, Oliynyk H, Korenkova S, Kumar J, Jagannath S, Moreau P, Levy M, White D, Gatt ME, Facon T, Mateos MV, Cavo M, Reece D, Anderson LD Jr, Saint-Martin JR, Jeha J, Joshi AA, Chai Y, Li L, Peddagali V, Arazy M, Shah J, Shacham S, Kauffman MG, Dimopoulos MA, Richardson PG, Delimpasi S. Grosicki S, et al. Among authors: gavriatopoulou m. Lancet. 2020 Nov 14;396(10262):1563-1573. doi: 10.1016/S0140-6736(20)32292-3. Lancet. 2020. PMID: 33189178 Clinical Trial.
Current Treatment Strategies for Multiple Myeloma at First Relapse.
Mavrothalassitis E, Triantafyllakis K, Malandrakis P, Gavriatopoulou M, Kleber M, Ntanasis-Stathopoulos I. Mavrothalassitis E, et al. Among authors: gavriatopoulou m. J Clin Med. 2025 Feb 28;14(5):1655. doi: 10.3390/jcm14051655. J Clin Med. 2025. PMID: 40095642 Free PMC article. Review.
Sustained bone marrow and imaging MRD negativity for 3 years drives discontinuation of maintenance post-ASCT in myeloma.
Terpos E, Malandrakis P, Ntanasis-Stathopoulos I, Kostopoulos IV, Eleutherakis-Papaiakovou E, Kanellias N, Spiliopoulou V, Migkou M, Fotiou D, Theodorakakou F, Kastritis E, Gavriatopoulou M, Tsitsilonis OE, Dimopoulos MA. Terpos E, et al. Among authors: gavriatopoulou m. Blood. 2025 May 15;145(20):2353-2360. doi: 10.1182/blood.2024027686. Blood. 2025. PMID: 40009496
Practical Guidance on Clinical Management of Belantamab Mafodotin-Associated Ocular Events.
Terpos E, Trudel S, Mateos MV, Alejandre N, Colby K, Dimopoulos MA, Esposti SD, Farooq AV, Gavriatopoulou M, Gay F, Hungria V, Kortüm KM, Leleu X, Lonial S, Quach H, Qiu L, Ramasamy K, Suzuki K, Weisel KC, Richardson P. Terpos E, et al. Among authors: gavriatopoulou m. Am J Hematol. 2025 Oct;100(10):1839-1850. doi: 10.1002/ajh.70015. Epub 2025 Jul 28. Am J Hematol. 2025. PMID: 40717676 Free PMC article.
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study.
Usmani SZ, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, Weisel K, Gavriatopoulou M, Oriol A, Rabin N, Nooka A, Qi M, Beksac M, Jakubowiak A, Ding B, Zahlten-Kumeli A, Yusuf A, Dimopoulos M. Usmani SZ, et al. Among authors: gavriatopoulou m. Lancet Oncol. 2022 Jan;23(1):65-76. doi: 10.1016/S1470-2045(21)00579-9. Epub 2021 Dec 3. Lancet Oncol. 2022. PMID: 34871550 Clinical Trial.
IMiDs for myeloma induced renal impairment.
Gavriatopoulou M, Terpos E, Dimopoulos MA. Gavriatopoulou M, et al. Oncotarget. 2018 Oct 26;9(84):35476-35477. doi: 10.18632/oncotarget.26270. eCollection 2018 Oct 26. Oncotarget. 2018. PMID: 30464802 Free PMC article. No abstract available.
321 results